The DOI matches its Crossref record.
Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study
Abstract
We treated 24 patients with narcolepsy for 4 weeks with gammahydroxybutyrate (GHB), 60 mg/kg/night, in a randomized double-blind placebo-controlled cross-over trial. Both clinical and polysomnographic criteria were used to assess the results. Compared to placebo, GHB reduced the daily number of hypnagogic hallucinations (from 0.87 to 0.28; p = 0.008), daytime sleep attacks (from 2.27 to 1.40; p = 0.001) and the severity of subjective daytime sleepiness (from 1.57 to 1.24 on a 0-4 scale; p = 0.028). The number of daily cataplexy attacks was reduced from 1.26 at baseline to 0.56 after 4 weeks of GHB intake. This reduction, however, was not statistically significantly different from the difference between baseline and placebo. GHB stabilized nocturnal rapid eye movement (REM) sleep, i.e. it reduced the percentage of wakefulness during REM sleep (p = 0.007) and the number of awakenings out of REM sleep (p = 0.016), and tended to increase slow wave sleep (p = 0.053). Adverse events were few and mild. We conclude that GHB is an effective and well-tolerated treatment for narcolepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Vankova, J., Black, J., Harsh, J., Bassetti, C., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1553 · Cited by 1,126
Self-citationDauvilliers, Y., Arnulf, I., & Mignot, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60237-2 · Cited by 725
PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY
NISHINO, S., & MIGNOT, E. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00070-6 · Cited by 449
Narcolepsy:Clinical Features, New Pathophysiologic Insights, and Future Perspectives
Overeem, S., Mignot, E., GertvanDijk, J., & Lammers, G. J. (2001) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-200103000-00002 · Cited by 333
Self-citationGHB: a new and novel drug of abuse
Nicholson, K. L., & Balster, R. L. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00191-5 · Cited by 320
What Keeps Us Awake: the Neuropharmacology of Stimulants and Wakefulness Promoting Medications
Boutrel, B., & Koob, G. F. (2004) · Sleep · doi:10.1093/sleep/27.6.1181 · Cited by 307
Kornum, B. R., Knudsen, S., Ollila, H. M., Pizza, F., Jennum, P. J., Dauvilliers, Y., & Overeem, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.100 · Cited by 285
Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence
Galloway, G. P., Frederick, S. L., Staggers, F. E., Gonzales, M., Stalcup, S. A., & Smith, D. E. (1997) · Addiction · doi:10.1046/j.1360-0443.1997.921899.x · Cited by 277
The neurobiology, diagnosis, and treatment of narcolepsy
Scammell, T. E. (2003) · Annals of Neurology · doi:10.1002/ana.10444 · Cited by 261
Excessive daytime sleepiness: A challenge for the practising neurologist
Guilleminault, C. (2001) · Brain · doi:10.1093/brain/124.8.1482 · Cited by 260
EFNS guidelines on management of narcolepsy
Billiard, M., Bassetti, C., Dauvilliers, Y., Dolenc‐Groselj, L., Lammers, G. J., Mayer, G., Pollmächer, T., Reading, P., & Sonka, K. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01473.x · Cited by 255
Self-citationVan Cauter, E., Plat, L., Scharf, M. B., Leproult, R., Cespedes, S., L'Hermite-Balériaux, M., & Copinschi, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119587 · Cited by 234
Neuroscience-driven discovery and development of sleep therapeutics
Dresler, M., Spoormaker, V. I., Beitinger, P., Czisch, M., Kimura, M., Steiger, A., & Holsboer, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.012 · Cited by 63
A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome
George, C. F. P., Feldman, N., Zheng, Y., Steininger, T. L., Grzeschik, S. M., Lai, C., & Inhaber, N. (2011) · Sleep and Breathing · doi:10.1007/s11325-009-0320-0 · Cited by 40
Metadata
- Authors
- Lammers, G. J., Arends, J., Declerck, A. C., Ferrari, M. D., Schouwink, G., & Troost, J.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-05
- Volume
- 16
- Issue
- 3
- Pages
- 216-220
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W2394759316
- Cited by
- 179
- References
- 0
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.